RNA has recently emerged as an important nanotechnology platform due to its extraordinary diversity in structure and function. Small interfering RNA (siRNA), showed significant potential in new molecular approaches to down-regulate specific gene expression in mammalian cells. In fact, targeted gene suppression by antisense DNA and siRNA has shown promising preclinical results, and/or is currently in clinical trials for a variety of diseases, including many forms of cancer (e.g., melanoma, neuroblastoma, and pancreatic adenocarcinoma), genetic disorders, and macular generation . Despite the high therapeutic potential of siRNA, its application for clinical medicine is still limited mainly due to the lack of appropriate delivery systems. In such a situation, the development of clinically suitable, safe, and effective drug-delivery biomaterials are required for the widespread use of siRNA therapeutics for disease treatment. These are subjected to peer-review by editorial board members who are highly qualified in that particular field. Only peer-reviewed general are accepted for publication. This process facilitates the meticulous evaluation of the content in the article there by maintaining high quality of the journal. Scholarly journals which publish original scientific work are called as research articles and those which revise already existing data in brief are known as review articles. Both these articles follow a formal specific and unambiguous format to avoid bias and confusion. All the data like graphs, reports and tables are presented to support the content. Usually advertising is not seen but can be added only if it is relevant to the field. OMICS Group International is one of the leading Open Access Publishers which is publishing 700+ peer-reviewed journals with the dramatic effort of world quality editorial board members. Molecular Biology publishes original research, review, and Short communication, Case study in the field of molecular biology.
Last date updated on July, 2014